EMA Issues Guidance On Compassionate Use Of Remdesivir For COVID-19
Executive Summary
Recommendations from the European Medicines Agency explain the conditions under which early access to remdesivir could be given through compassionate use programs.
You may also be interested in...
EMA Clarifies Fast-Track Mechanisms For COVID-19 Medicines & Vaccines
From speeding up PIP agreements to starting rolling reviews, the European Medicines Agency has explained how it is accelerating its regulatory procedures for COVID-19 treatments and vaccines.
Coronavirus Update: iSPOCs, Fake Drugs & Data Protection Concerns
In addition to our daily in-depth coverage of key events relating to the COVID-19 pandemic, we’re bringing you a periodic round-up of other developments. This edition covers events at EU and member state level, as well as initiatives by international regulators.
Regulators Insist On Large-Scale Trials For Coronavirus Treatment Candidates
At their second meeting on COVID-19, drug regulators from around the world have stressed the importance of large, multi-arm studies in generating the data needed for the approval of potential coronavirus therapies. The European Medicines Agency, which organized the meeting, has also announced a new coronavirus task force to identify promising drug candidates and help steer them through development to regulatory approval.